
*** TX REPORT ***

TRANSMISSION OK

TX/RX NO 2744
CONNECTION TEL 914132549245
SUBADDRESS
CONNECTION ID
ST. TIME 08/21 11:32
USAGE T 05'48
PGS. 4
RESULT OK



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Fax Cover Sheet

Date: 21 Aug 2001

| | |
|--|------------------------------|
| To: Vivian Amzel | From: J Epps |
| Application/Control Number: 09/093,972 | Art Unit: 1635 |
| Fax No.: (1) 1-413-254-9245 | Phone No.: 703-308-8883 |
| Voice No.: | Return Fax No.: 703-305-7939 |
| Re: | CC: |

☐ Urgent ☐ For Review ☐ For Comment ☐ For Reply ☒ Per Your Request

Comments:

A copy of the Advisory Action mailed 7-23-01



OFFICIAL

8-21-01

7 Clarke Drive
Cranbury, New Jersey 08520
Telephone: (609) 409-6080
Direct Facsimile: (413) 254-9245
Main Facsimile: (609) 409-6126

FAX COVER SHEET

To: Dr. Janet Epps

Company: US PTO -GAU

Fax No: 703-305-7939

From: Viviana Amzel Date: 8/21/01 Time: _____

Direct Dial: (409) 609-3035 E-Mail: vamzel@epigene.com

Pages including this: 34 Ref. No.: USSN 09/093,972 (EPI-00672)

COMMENTS

This is a Supplemental Amendment that takes care of the last issues in the case. Please fax me a Notice of Allowance. Thanks.

CONFIDENTIALITY NOTICE

The information in this fax transmission and the documents accompanying it contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone to arrange for return of the original documents to us.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce : Art Unit: 1635
Serial No.: 09/093,972 : Examiner: J. Epps
Filed: June 9, 1998 : Appl. Ref. No.: EPI-00672
For: **COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION &
TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION**

COVER SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:


Enclosed for filing are the following:

1. Supplemental
2. Claims (marked up)
3. Claims (clean)
4. This cover sheet
5. Fax Cover Sheet
6. Page 38

Respectfully submitted.
EPIGENESIS PHARMACEUTICALS, INC.


August 21, 2001

Date


Viviana Amzel, Ph. D.
Reg. No. 30930
Attorney for Applicant(s)

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Legal Dpt Ph.
413-254-9245 Legal Dpt Fax
Vamzel@EpiGene.com

I hereby certify that this correspondence is being faxed at
703-305-7939, to the Assistant Commissioner for Patents,
Arlington, VA 22202, on August 21, 2001, by Rashida Haji.


SIGNATURE

S:\Legal\00672\Cover Sheet 01-8-21

S:\Legal\00672 AS PARTICLE SIZE\Cover Sheet 01-8-21.doc

SERIAL NO: 09/093,972

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce : Art Unit: 1635
Serial No.: 09/093,972 : Examiner: Dr. Epps
Filed: June 9, 1998 : Appl. Ref. No.: EPI-00672
For: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION &
TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION

SUPPLEMENTAL AMENDMENT

I hereby certify that this correspondence is being faxed at 703-305-7939, to the Assistant Commissioner for Patents, Washington DC 20231 on August 21, 2001, by Rashida Haji.

SIGNATURE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

Supplemental to the Response to the Office Action of November 7, 2000, filed March 28, 2001, a Notice of Appeal having been filed May 4, 2001, and Supplemental Amendments filed July 12 and 16, 2001, the period for responding having been extended to September 7, 2001 by the filing of a Petition and a fee of \$195.- on July 12, 2001, please amend the above identified patent application as follows.

THE SEQUENCE LISTING

Please disregard the Sequence Listing section filed May 4, 2000, and substitute therefor the one filed March 22, 2001.

IN THE SPECIFICATION

Please amend the specification as follows.

Paragraph bridging pages 37 and 38, change as follows:

In the anti-sense oligonucleotides of the present invention, exemplified by the preceding sequences, a number of adenosine bases may be replaced with an appropriate "spacer" or universal base, [C] e.g., 1- $[\beta$ -D-2'-deoxyribofuranosyl]-5-nitroindole], or with an adenosine agonist or antagonist that does not stimulate adenosine A₁, A_{2b} or A₃ receptors, but which may stimulate adenosine A_{2a} receptors. In this manner, a specific adenosine receptor gene may be targeted to obtain one or more anti-sense oligonucleotide(s) (oligos) that selectively bind(s) to

Do not Enter
9-17-01 JE

#42/K
BP
8-22-01
(NE)